Scarica l'app Stockscreener
24.15
4.24%
-1.07
Dopo l'orario di chiusura:
24.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$25.22
Aprire:
$25.22
Volume 24 ore:
1.54M
Relative Volume:
0.64
Capitalizzazione di mercato:
$3.05B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-11.90
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-6.14%
1M Prestazione:
+1.39%
6M Prestazione:
+32.98%
1 anno Prestazione:
-13.60%
Intervallo 1D:
$24.04
$25.73
Intervallo di 1 settimana:
$23.10
$25.99
Portata 52W:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
24.15 | 2.92B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
(APLS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results - The Manila Times
Apellis Pharma director Dunlop A. Sinclair sells $737k in APLS - Investing.com India
Apellis Pharmaceuticals Shares Rise After Wells Fargo Upgrade - MarketScreener
Why retail investors pile into Apellis Pharmaceuticals Inc. stockPortfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Apellis Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.Trade Risk Assessment & Advanced Swing Trade Entry Plans - newser.com
Wells Fargo Upgrades Apellis Pharmaceuticals (APLS) to Overweigh - GuruFocus
What high frequency data says about Apellis Pharmaceuticals Inc.Quarterly Earnings Report & Real-Time Volume Trigger Notifications - newser.com
Earnings call transcript: Apellis Pharmaceuticals Q2 2025 reveals revenue growth - Investing.com Australia
Apellis Q2 2025 slides: Revenue dips despite EMPAVELI approval for kidney diseases - Investing.com UK
APLS Crosses Below Key Moving Average Level - Nasdaq
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedMarket Trend Report & Fast Momentum Stock Entry Tips - newser.com
Key resistance and support levels for Apellis Pharmaceuticals Inc.Earnings Recap Summary & Daily Profit Maximizing Trade Tips - newser.com
Can Apellis Pharmaceuticals Inc. stock surprise with earnings upsideTrade Performance Summary & Target Return Focused Stock Picks - newser.com
How to integrate Apellis Pharmaceuticals Inc. into portfolio analysis tools2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Applying chart zones and confluence areas to Apellis Pharmaceuticals Inc.Earnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
How to forecast Apellis Pharmaceuticals Inc. trends using time seriesQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Using R and stats models for Apellis Pharmaceuticals Inc. forecastingDividend Hike & Proven Capital Preservation Tips - newser.com
Eastern Bank Cuts Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What analysts say about Apellis Pharmaceuticals Inc stockVWAP Trading Strategies & Master Stock Selection - earlytimes.in
Complement 3 Glomerulopathy Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | ChemoCentryx, Novartis, Omeros Corporation, Apellis Pharma - Barchart.com
Price momentum metrics for Apellis Pharmaceuticals Inc. explainedQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
Using Bollinger Bands to evaluate Apellis Pharmaceuticals Inc.Quarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Identifying reversal signals in Apellis Pharmaceuticals Inc.2025 Performance Recap & AI Driven Stock Reports - newser.com
Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffs - fiercebiotech.com
How to monitor Apellis Pharmaceuticals Inc. with trend dashboardsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Using data tools to time your Apellis Pharmaceuticals Inc. exitJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Raises Target Price to $28 - 富途牛牛
Published on: 2025-10-05 07:38:09 - newser.com
Volume spikes in Apellis Pharmaceuticals Inc. stock – what they meanJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock sustain institutional flows2025 Price Momentum & Smart Money Movement Tracker - newser.com
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price action2025 Market Outlook & Verified Swing Trading Watchlist - newser.com
Candlestick signals on Apellis Pharmaceuticals Inc. stock todayWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
J. Safra Sarasin Holding AG Buys 68,588 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - MSN
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
What Fibonacci levels say about Apellis Pharmaceuticals Inc. reboundTrade Signal Summary & Entry Point Strategy Guides - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apellis Pharmaceuticals Inc Azioni (APLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dunlop A. Sinclair | Director |
Sep 30 '25 |
Sale |
22.58 |
31,092 |
702,057 |
33,979 |
| Dunlop A. Sinclair | Director |
Sep 19 '25 |
Sale |
22.95 |
31,092 |
713,561 |
68,908 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):